ARCT - Why Arcturus Therapeutics Stock Is Soaring Today
Shares of Arcturus Therapeutics (NASDAQ: ARCT) were soaring 34.7% higher as of 10:56 a.m. EDT on Tuesday. The big jump came after the company announced that Singapore regulators approved the advancement of two messenger RNA COVID-19 vaccine candidates into phase 1/2 clinical testing.
The Singapore Health Sciences Authority gave the green light for Arcturus to initiate a phase 1/2 clinical trial featuring mRNA vaccine candidates ARCT-154 and ARCT-165. This study will evaluate these candidates as primary vaccines and as boosters following initial vaccination with Comirnaty, the COVID-19 vaccine developed by Pfizer and BioNTech .
Image source: Getty Images.
For further details see:
Why Arcturus Therapeutics Stock Is Soaring Today